884 related articles for article (PubMed ID: 28636593)
1. T cells from patients with Parkinson's disease recognize α-synuclein peptides.
Sulzer D; Alcalay RN; Garretti F; Cote L; Kanter E; Agin-Liebes J; Liong C; McMurtrey C; Hildebrand WH; Mao X; Dawson VL; Dawson TM; Oseroff C; Pham J; Sidney J; Dillon MB; Carpenter C; Weiskopf D; Phillips E; Mallal S; Peters B; Frazier A; Lindestam Arlehamn CS; Sette A
Nature; 2017 Jun; 546(7660):656-661. PubMed ID: 28636593
[TBL] [Abstract][Full Text] [Related]
2. Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases.
Lindestam Arlehamn CS; Garretti F; Sulzer D; Sette A
Curr Opin Immunol; 2019 Aug; 59():115-120. PubMed ID: 31430650
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.
Garretti F; Agalliu D; Lindestam Arlehamn CS; Sette A; Sulzer D
Front Immunol; 2019; 10():303. PubMed ID: 30858851
[TBL] [Abstract][Full Text] [Related]
4. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease.
Caggiu E; Paulus K; Galleri G; Arru G; Manetti R; Sechi GP; Sechi LA
J Neuroimmunol; 2017 Sep; 310():26-31. PubMed ID: 28778441
[TBL] [Abstract][Full Text] [Related]
5. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
[TBL] [Abstract][Full Text] [Related]
6. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
7. T cells, α-synuclein and Parkinson disease.
Garretti F; Monahan C; Sette A; Agalliu D; Sulzer D
Handb Clin Neurol; 2022; 184():439-455. PubMed ID: 35034753
[TBL] [Abstract][Full Text] [Related]
8. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
[TBL] [Abstract][Full Text] [Related]
9. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.
Blazevic V; Ranki A; Krohn KJ
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1335-42. PubMed ID: 8573390
[TBL] [Abstract][Full Text] [Related]
10. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
Shen L; Schroers R; Hammer J; Huang XF; Chen SY
Cancer Immunol Immunother; 2004 May; 53(5):391-403. PubMed ID: 14624313
[TBL] [Abstract][Full Text] [Related]
11. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Gallups NJ; Standaert DG; Harms AS
Brain; 2021 Aug; 144(7):2047-2059. PubMed ID: 33704423
[TBL] [Abstract][Full Text] [Related]
12. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
13. Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1).
da Silva J; Hughes AL
Mol Biol Evol; 1998 Oct; 15(10):1259-68. PubMed ID: 9787432
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
16. The major histocompatibility complex participates in Parkinson's disease.
Gu R; Pan J; Awan MUN; Sun X; Yan F; Bai L; Bai J
Pharmacol Res; 2024 May; 203():107168. PubMed ID: 38583689
[TBL] [Abstract][Full Text] [Related]
17. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
18. The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?
Jiang T; Li G; Xu J; Gao S; Chen X
Front Immunol; 2018; 9():2047. PubMed ID: 30319601
[TBL] [Abstract][Full Text] [Related]
19. Immunologic treatment of Parkinson's disease.
Jankovic J
Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
[No Abstract] [Full Text] [Related]
20. Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
Bandres-Ciga S; Cookson MR
Mov Disord; 2017 Sep; 32(9):1327. PubMed ID: 28782845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
